Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml

International Journal of Radiation Oncology Biology Physics

Volumn 37, Issue 5, 1997, Pages 1053-1058

  D'Amico, Anthony V ^a,d   Whittington, Richard ^b   Kaplan, Irving ^a   Beard, Clair ^a   Jiroutek, Michael ^c   Malkowicz, S Bruce ^b   Wein, Alan ^b   Coleman, C Norman ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

Author keywords

Gleason score; Prostate cancer; Prostate specific antigen; Radiation therapy; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BEAM THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; TREATMENT FAILURE;

DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REFERENCE VALUES; RETROSPECTIVE STUDIES;

EID: 0030942674     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(96)00633-5     Document Type: Article

References (32)

1. Beahrs, O. H.; Henson, D. E.; Hutter, R. V. P.; Kennedy, B. J. American Joint Committee on Cancer manual for staging cancer, 4th ed. Philadelphia, PA: J. P. Lippincott; 1992.
2. Catalona, W. J.; Smith, D. S. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol. 152:1837-1842; 1994.
3. Chodak, G. W.; Thisted, R. A.; Gerber, G. S.; Johansson, J. E.; Adolfsson, J,; Jones, G. W.; Chisholm, G. D.; Moskovitz, B.; Livine, P. M.; Warner, J. Results of conservative management of clinically localized prostate cancer. N. Engl. J. Med. 330:242-248; 1994.
4. Cox, D. R. Regression models and life tables. J. R. Stat. Soc. B34:1; 1972.
5. D'Amico, A. V.; Whittington, R.; Malkowicz, S. B.; Schnall, M.; Tomaszewski, J. E.; Schultz, D.; Wein, A. A multivariate analysis of clinical and pathological factors which predict for prostate-specific antigen failure after radical prostatectomy after prostate cancer. J. Urol. 154:131-138; 1995.
6. Frazier, H. A.; Robertson, J. E.; Humphrey, P. A.; Paulson, D. F. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J. Urol. 149:516; 1993.
7. Hanks, G. E. More on the Uro-Oncology Research Group report of radical surgery versus radiotherapy for adenocarcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys, 14:1053-1057; 1988.
8. Hanks, G. E.; Hanlon, A. L.; Hudes, G.; Lee, W. R.; Winlove, S.; Schultheiss, T. Patterns-of-failure analysis of patients with high pretreatment prostate-specific-antigen levels treated by radiation therapy: The need for improved systemic and local regional therapy. J. Clin. Oncol. 14:1093-1097; 1996.
9. Hanks, G. E.; Perez, C. A.; Kozar, M. B.; Asbell, S. O.; Pilepich, M. V.; Kaplan, R, Prostate specific antigen confirmation of long term cure of prostate cancer treated by external beam radiation in the RTOG. Int. J. Radiat. Oncol. Biol. Phys. 27 (Suppl. 1): 192; 1993 (abstr).
10. Jaroff, L. The man's cancer. Time Magazine. 147:58-66; April 1, 1996.
11. Kaplan, I. D.; Cox, R. S.; Bagshaw, M. A. Prostate specific antigen after external beam radiotherapy for prostatic cancer: Followup. J. Urol. 149:519; 1993.
12. Kaplan, E. L.; Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:457-481; 1958.
13. Kuban, D. A.; El-Mahdi. A. M.; Schellhammer, P. F. Prostate-specific antigen for pretreatment and post-treatment evaluation of outcome after definitive irradiation for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:307-316; 1995.
14. Kupelian, P.; Levin, H.; Zippe, C.; Klein, E. A contemporary series of external beam radiotherapy versus radical prostatectomy for localized prostate cancer: A single institution experience: Proceedings of the 32nd meeting of ASCO. J. Clin. Oncol. 15:252; 1996 (abstr).
15. Lange, P. H.; Ercole, C. J.; Lightner, D. J.; Fraley, E. E.; Vessella, R. The value of prostate specific antigen determinations before and after radical prostatectomy. J. Urol. 141:873; 1989.
16. Myrtle, J. F.; Klimley, P. G.: Ivor, L. P.; and Brun, J. F.; Clinical utility of prostate-specific antigen (PSA) in the management of prostate cancer. Adv. Cancer Diagn. Hybritech, Inc., San Diego, CA.; 1986.
17. Ohori, M.; Wheeler, T. M.; Dunn, J. K.; Stamey, T. A.; Scardino, P. T. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J. Urol. 152:1714-1720; 1994.
18. Partin, A. W.; Pound, C. R.; Quentin Clemens, J.; Epstein, J. I.; Walsh, P. C. Serum PSA after anatomic radical prostatectomy, The Johns Hopkins experience after 10 years. Urol. Clin. N. Am. 20:713; 1993.
19. Paulson, D. F.; Lin, G. H.; Hinshaw, W.; Stephani, S.; and the Uro-Oncology Research Group. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J. Urol. 128:502; 1982.
20. Pisansky, T. M.; Cha, S. S.; Earle, J. D.; Durr, E. D.; Kozelsky, T. F.; Wieand, S.; Oesterling, J. E. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J. Clin. Oncol. 11:2158; 1993.
21. Ritter, M. A.; Messing, E. M.; Shanahan, T. G.; Potts, S.; Chappell, R. J.; Kinsella, T. S. Prostate specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J. Clin. Oncol. 10:1208; 1992.
22. Rosenzweig, K. E.; Morgan, W. R.; Lytton, B.; Peschel, R. E. Prostate specific antigen following radiotherapy for local prostate cancer. J. Urol. 153:1561; 1995.
23. Sandler, H. M.; McLaughlin, P. W.; Kish, K. E.; Lichter, A. Results of 3D conformal radiotherapy for the treatment of 707 patients with localized prostate cancer: Proceedings of the 37th ASTRO. Int. J. Radiat. Oncol. Biol. Phys. 32(Suppl. 1):141; 1995 (abstr).
24. Schellhammer, P. F.; El-Mahdi, A. M.; Wright, G. L.; Kolm, P.; Rale, R. Prostate-specific antigen to determine progression free survival after radiation therapy for localized carcinoma of the prostate. Urology 42:13; 1993.
25. Stein, A.; de Kernion, J. B.; Smith, R. B.; Dorey, F.; Patel, H. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate carcinoma. J. Urol. 147:942; 1992.
26. Talcott, J. A.; Rieker, P.; Propert, K. J.; Clark, J.; Kantoff, P.; Beard, C.; Kaplan, I.; Loughlin, K.; Richie, J.; Wishnow, K. Long-term complications of treatment for early prostate cancer: 2-year followup in a prospective multi-institutional outcomes study: Proceedings of the 32nd meeting of ASCO. J. Clin. Oncol. 15:252; 1996 (abstr).
27. Trapasso, J. G.; deKernion, J. B.; Smith, R. B.; Dorey, F. Incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. Urol. 152:1821-1825; 1994.
28. Zagars, G. K.: Prostate specific antigen as outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol. 152:1786-1791; 1994.
29. Zagars, G. K.; Pollack, A.; Von Eschenbach, A. C. Prostate cancer and radiation therapy - The message conveyed by serum prostate-specific antigen. Int J. Radiat. Oncol. Biol. Phys. 33:23-35; 1995.
30. Zietman, A. L.; Coen, J. J.; Shipley, W. U.; Efird, J. Radical radiation therapy in the management of prostate adenocarcinoma: The initial PSA value as a predictor of treatment outcome. J. Urol. 151:640; 1994.
31. Zietman, A. L.; Edelstein, R. A.; Coen, J. J.; Babayan, R. K.; Krane, R. J. Radical prostatectomy for adenocarcinoma of the prostate: The influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 43:828; 1994.
32. Zietman, A. L.; Shipley, W. U.; Coen, J. J. Radical prostatectomy and radical radiation therapy for clinical Stages T1 to 2 adenocarcinoma of the prostate: New insights into outcome from repeat biopsy and prostate specific antigen followup. J. Urol. 152:1806-1812; 1994.